TransCode Therapeutics, Inc.
RNAZ · Price history
Price at last available close
$1.74
+$0.11 (+6.75%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About TransCode Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B.
How they make money
TransCode Therapeutics is a clinical-stage biopharmaceutical company that has not yet generated revenue. Its business model relies on developing and commercializing RNA-based oncology therapeutics, funded through equity offerings, strategic partnerships, and potential future licensing or collaboration agreements.
Products & services
The company is developing a modular RNA delivery platform, with its lead therapeutic candidate, TTX-MC138, designed to inhibit the survival of metastatic tumor cells.
Brands & revenue mix
Proprietary delivery platform for RNA therapeutics.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Oncology patientsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for preclinical studies, clinical trials, and the manufacturing of drug candidates; specific supplier names are not disclosed.Source
Business relationships & partnerships
- The General Hospital Corporation (Massachusetts General Hospital) — Academic research collaboration and licensing agreement for the development of the core TTX delivery platform and therapeutic targets.Source
- The University of Texas MD Anderson Cancer Center — Research alliance to collaborate on preclinical studies validating therapeutic and diagnostic candidates.Source
Strengths
- Modular RNA delivery platform technologySource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
31
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
41
Weak
Financial Strength
65
Business Quality / Moat
0
Management
40
Growth Quality
89
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Balance-sheet / debt profile scores strongly
- •Asset quality scores strongly
- •Debt service risk
- •Valuation is a weaker part of the current profile
Company-specific research
Questions worth answering for RNAZ
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can RNAZ fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is RNAZ likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for RNAZ to reach sustainable profitability?
- •What future growth or profitability would be needed to justify RNAZ's current valuation?
- •What does the current none warning mean for the reliability or interpretation of RNAZ's score?
Essential Investment Snapshot
Wall Street Score
31
Market Cap
$1.8M
P/E Ratio
-0.0
EPS
$-50.69
52-Week High
$13.96
52-Week Low
$1.52
Beta
1.26
Shares Outstanding
690K
Total Revenue
$0
Total Debt
$652K
Dividend
No current dividend
Liquidation Value / Share
$200.60
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for RNAZ
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-4229.2x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on RNAZ.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Modular RNA delivery platform technology.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and lack of revenue.
- −Dependence on third-party manufacturers and clinical research organizations.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
31
Oct 15, 2026
Change
Unchanged
Current Score
31
Oct 23, 2026
Category Changes
RNAZ score was unchanged.
Projected Score
Projected Score
36
Projected Change
+4.7 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.7 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.74
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $53K | $0.00 | $535K | $517K | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$53K | $0.00 | -$535K | -$517K | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $5.12B | $13.4M | $9.6M | $12.3M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $2.23B | $5.8M | $5.5M | $6.6M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $34.7M | $28.0M | $15.1M | $18.9M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$42.3M | -$34.3M | -$16.2M | -$18.0M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$34.7M | -$28.0M | -$15.7M | -$19.4M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $7K | $7K | $27K | $56K | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$42.4M | -$34.4M | -$16.8M | -$18.5M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $457K | $226K | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$42.8M | -$34.7M | -$16.8M | -$18.5M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-50.69 | $-52.59 | $-47.14 | $-3453.65 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 937K | 690K | 356K | 5.4K | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 937K | 690K | 356K | 5.4K | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$7.17
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
+13.7%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
Potential Score Impact
Positive indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 39.8%. Cash increased 13.7%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
Rumor Mill · RNAZ
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial